Biomarker: | FLT3-ITD mutation + MLL fusion + TP53 mutation |
---|---|
Cancer: | Acute Myelogenous Leukemia |
Drug: | sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor) + crenolanib (ARO-002) (FLT3 inhibitor, PDGFR α inhibitor, PDGFR β inhibitor) |
Direction: | Sensitive |